CAJ | 학술논문

目的探讨多西他赛联合表柔吡星治疗乳腺癌的疗效及不良反应.方法将120例晚期乳腺癌患者随机分为观察组和对照组,每组60例.观察组采用多西他赛联合表柔吡星治疗;对照组采用环磷酰胺联合5-氟尿嘧啶、阿霉素治疗,比较两组患者的临床疗效及毒副反应.结果观察组CR 8例, PR36例,近期总有效率为73.3%(44/60),显著高于对照组的近期总有效率26.7%(16/60)( P <0.05);不良反应为脱发、厌食疲乏、恶心呕吐、白细胞下降等,多数患者能耐受.结论多西他赛联合表柔吡星治疗乳腺癌的疗效肯定,毒副反应小,患者能耐受,值得推广.
목적탐토다서타새연합표유필성치료유선암적료효급불량반응.방법장120례만기유선암환자수궤분위관찰조화대조조,매조60례.관찰조채용다서타새연합표유필성치료;대조조채용배린선알연합5-불뇨밀정、아매소치료,비교량조환자적림상료효급독부반응.결과관찰조CR 8례, PR36례,근기총유효솔위73.3%(44/60),현저고우대조조적근기총유효솔26.7%(16/60)( P <0.05);불량반응위탈발、염식피핍、악심구토、백세포하강등,다수환자능내수.결론다서타새연합표유필성치료유선암적료효긍정,독부반응소,환자능내수,치득추엄.
Objective To assess the efficacy and safety of docetaxel plus pirarubicin(THP) in treating breast cancer. Methods 120 patients with advanced carcinoma of large intestine were randomly divided into trial group and control group, and each group was 60 patients. Patients in the trial group were treated with docetaxel plus pirarubicin(THP) while the control group were treated with the combination of cyclophosphamide(CTX)+ doxorubicin(ADM)+Fluorouracil(5-FU). Then the the clinical curative effects and toxical effects in two groups were compared. Results For the trial group, 8 patient reached complete response (CR), 36 partial response (PR). The overal response rate (CR+PR) was 73.3% (44/60), and looked higher than that of controled group (26.7%) (16/60) (P<0.05). Conclusion docetaxel plus pirarubicin(THP) in treating breast cancer had higher response rate, lower toxicity, longer median survival and better quality of life.